Recap: Blueprint Medicines Q4 Earnings
Recap: Blueprint Medicines Q4 Earnings
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62).
Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000.
Looking Ahead
Blueprint Medicines hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Feb 17, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy
Recent Stock Performance
Company's 52-week high was at $125.61
52-week low: $43.29
Price action over last quarter: down 8.88%
Company Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results.
的股份藍圖藥品(納斯達克：BPMC)在公司公佈第四季度業績後保持不變。
Quarterly Results
季度業績
Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62).
過去一年每股獲利下滑13.33%至(1.53美元)，超過預估的(1.62美元)。
Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000.
營收為34,107,000美元，較去年同期下降33.82%，超過預期的29,240,000美元。
Looking Ahead
展望未來
Blueprint Medicines hasn't issued any earnings guidance for the time being.
Blueprint Medicines暫時沒有發佈任何盈利指引。
Revenue guidance hasn't been issued by the company for now.
該公司目前尚未發佈營收指引。
How To Listen To The Conference Call
如何收聽電話會議
Date: Feb 17, 2021
日期：2021年2月17日
Time: 08:30 AM
時間：上午8時30分
ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy
Recent Stock Performance
近期股市表現
Company's 52-week high was at $125.61
該公司52周高點為125.61美元
52-week low: $43.29
52周低點：43.29美元
Price action over last quarter: down 8.88%
上季度價格走勢：下跌8.88%
Company Description
公司描述
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Blueprint Medicines Corp是一家生物製藥公司。它的重點是改善由異常激酶激活引起的疾病患者的生活。該公司已經開發出一種治療癌症和一種罕見遺傳病的小分子藥物流水線。它的候選藥物BLU-285針對KIT Exon 17突變體和PDGFRA D842V，這是一種異常活躍的受體酪氨酸激酶突變體，是癌症和增殖性疾病的驅動因素。它的另一個候選藥物是用於晚期肝細胞癌的BLU 554，以及用於Ret突變、融合和預測耐藥突變的BLU-667。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧